NCT00411086 - Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions

Lymphoma

Interventions

BIOLOGICAL

Rituximab

375 mg/m\^2 By Vein Weekly on Days 1, 8, 15, and 22.

BIOLOGICAL

Sargramostim (GM-CSF)

250 mcg subcutaneously three times weekly for 8 weeks, starting at least 1 hour before first dose of rituximab.

Trial Locations (1)

University of Texas MD Anderson Cancer Center, Houston